Subscribe or Manage Preferences
June 30, 2015, was the deadline for submission of practice-based applications to the Center for Medicare and Medicaid Innovation (CMMI) for the Oncology Care Model (OCM). The dust has settled. Those who were going to apply have done so, and those who decided not to, have watched the hustle and bustle during June with some amusement.
Patients who have not had meaningful discussions with clinicians about end-of-life care—including chemotherapy, cardiopulmonary resuscitation, and referral for hospice care—have an increased likelihood of receiving inappropriate, aggressive care at the end of life.
In an effort to contain healthcare costs and to improve the quality of cancer care via shared decision-making, the ASCO Value in Cancer Care Task Force developed a conceptual framework to assess the value of new cancer drugs versus current standard-of-care treatments in 2 clinical settings: advanced disease and potentially curative disease.
Burnout among oncology providers hinders thriving and development at the individual level and delivery of value at the system level, said 2 experts during a practice management session at the 2015 American Society of Clinical Oncology annual meeting.
Although still evolving, oncology medical homes have demonstrated the ability to improve patient care, outcomes, and satisfaction while saving money, agreed speakers at a practice management session at the 2015 American Society of Clinical Oncology annual meeting.
Attendees at the 2015 Association for Value-Based Cancer Care conference heard Robert “Bo” Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance (COA), describe recent accreditation initiatives for the oncology medical home (OMH) model.
Public and private payers, policy advisors, and oncologists and nurses from the audience debated how to measure quality in cancer care during a panel discussion at the 2015 Association for Value-Based Cancer Care conference. John Fox, MD, MHA, Senior Medical Director and Associate Vice President of Medical Affairs, Priority Health moderated the discussion.
The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders. According to one breast cancer advocate, when patients are asked to define “value” in the context of their cancer treatment, cost is not the first thing that comes to mind.
Payment models that align reimbursement to support treatment planning and care coordination encourage oncology care providers to adhere to cancer treatment pathways, said Jennifer Malin, MD, PhD, Staff Vice President for Clinical Strategy, Anthem, Thousand Oaks, CA, at the 2015 American Society of Clinical Oncology annual meeting.
As most state legislatures adjourn from their 2015 session, we have begun to reflect on key policy trends emerging this year. In terms of policy impacting cancer care, efforts to limit patient exposure to rising drug costs and maintain access to potentially life-saving treatments have continued to grow, and we are seeing an increase in the number of bills introduced by state legislators and the number of policy approaches regarding these issues. Although there was a focus on achieving oral chemotherapy parity over the past several years, we now see broad proposals to cap copays, limit the use of specialty drug tiers, and limit the use of step therapy.
Stakeholders in the healthcare system are making an effort to ensure that people are not squeezed out of the practice of medicine by insufficient time and support to comply with ICD-10.
The following clinical trials are currently recruiting patients with myelodysplastic syndrome for inclusion in a variety of studies targeting specific subpopulation of patients with this syndrome. Each trial description includes the NLM Identifier to use as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their appropriate patients to a specific clinical trial described here.
Page 1 of 2
Results 1 - 12 of 14
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search